Amphastar Pharmaceuticals Reports 75% Drop in Q1 GAAP Net Income
AMPH sits 27% above its 52-week low of $17.03.
Summary
Amphastar Pharmaceuticals, Inc. announced its first-quarter 2026 financial results, reporting a significant 75% year-over-year decline in GAAP net income and a substantial drop in diluted EPS, despite flat net revenues.
Key Events · Earnings and Guidance · AMPH
-
GAAP Net Income Plummets
Reported GAAP net income of $6.4 million for Q1 2026, a 75% decrease from $25.3 million in Q1 2025.
-
Diluted EPS Declines Sharply
GAAP diluted EPS fell to $0.14 for Q1 2026, down from $0.51 in the prior year's quarter.
-
Gross Margin Compression
Gross profit decreased by 18% to $70.3 million, with gross margin falling from 50.0% to 41.1% of net revenues.
-
Flat Net Revenues
Net revenues remained largely flat at $171.2 million compared to $170.5 million in Q1 2025.
Analysis · AMPH · Life Sciences
Amphastar Pharmaceuticals, Inc. announced its first-quarter 2026 financial results, reporting a significant 75% year-over-year decline in GAAP net income and a substantial drop in diluted EPS, despite flat net revenues. This significant decline was primarily driven by lower gross margins on key products like BAQSIMI® and glucagon, coupled with increased manufacturing, legal, and R&D expenses, including a $2.0 million upfront payment for a new licensing agreement. While net revenues remained flat, the substantial reduction in profitability and gross margin compression indicate significant operational challenges and competitive pressures, which could impact investor sentiment and future earnings expectations.
At the time of this filing, AMPH was trading at $21.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $17.03 to $31.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.